0HFR logo

Anavex Life Sciences LSE:0HFR Stock Report

Last Price

US$12.12

Market Cap

US$1.0b

7D

40.6%

1Y

28.5%

Updated

29 Dec, 2024

Data

Company Financials +

Anavex Life Sciences Corp.

LSE:0HFR Stock Report

Market Cap: US$1.0b

0HFR Stock Overview

A clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. More details

0HFR fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 98% below our estimate of its fair value

Earnings are forecast to grow 47.12% per year

Risk Analysis

Highly volatile share price over the past 3 months compared to the UK market

Makes less than USD$1m in revenue ($0)

Shareholders have been diluted in the past year


My Notes

Capture your thoughts, links and company narrative

Anavex Life Sciences Corp. Competitors

Genus

LSE:GNS

UK£998.5m

Oxford Biomedica

LSE:OXB

UK£446.5m

PureTech Health

LSE:PRTC

UK£366.3m

Faron Pharmaceuticals Oy

AIM:FARN

UK£180.5m

Price History & Performance

Summary of share price highs, lows and changes for Anavex Life Sciences
Historical stock prices
Current Share PriceUS$12.12
52 Week HighUS$14.45
52 Week LowUS$3.30
Beta0.73
1 Month Change28.26%
3 Month Change115.72%
1 Year Change28.55%
3 Year Change-30.88%
5 Year Changen/a
Change since IPO301.44%

Recent News & Updates

Recent updates

Shareholder Returns

0HFRGB BiotechsGB Market
7D40.6%0.2%0.8%
1Y28.5%-26.1%2.7%

Return vs Industry: 0HFR exceeded the UK Biotechs industry which returned -26.1% over the past year.

Return vs Market: 0HFR exceeded the UK Market which returned 2.7% over the past year.

Price Volatility

Is 0HFR's price volatile compared to industry and market?
0HFR volatility
0HFR Average Weekly Movement16.0%
Biotechs Industry Average Movement7.0%
Market Average Movement4.7%
10% most volatile stocks in GB Market10.4%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0HFR's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0HFR's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
200442Chris Misslingwww.anavex.com

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. The company’s lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer’s disease and Parkinson’s disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. It also provides ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer’s disease.

Anavex Life Sciences Corp. Fundamentals Summary

How do Anavex Life Sciences's earnings and revenue compare to its market cap?
0HFR fundamental statistics
Market capUS$1.03b
Earnings (TTM)-US$43.00m
Revenue (TTM)n/a

0.0x

P/S Ratio

-23.9x

P/E Ratio

Is 0HFR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0HFR income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$43.00m
Earnings-US$43.00m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.51
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 0HFR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 18:22
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Anavex Life Sciences Corp. is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Caroline PalomequeBerenberg
Yun ZhongBTIG
Charles DuncanCantor Fitzgerald & Co.